CancerDrs

Breast Cancer clinical trials in Missouri

48 actively recruiting breast cancer trials at 26 sites across Missouri.

Data from ClinicalTrials.gov · last refreshed

Payments from drug makers to the doctors running these trials

For 2 of the trials on this page, the pharmaceutical company funding the trial also disclosed payments to the physicians leading it — public data from the federal CMS Open Payments database. Paying clinical-trial investigators for site work is expected and necessary for industry-funded trials; the scale and source are simply useful context when you're deciding whether to enroll. See the full breast cancer transparency page →

Phase 3 Recruiting Academic/Other

Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25

This Phase III Trial will determine whether adjuvant chemotherapy (ACT) added to ovarian function suppression (OFS) plus endocrine therapy (ET) is superior to OFS plus ET in improving invasive breast cancer-free survival (IBCFS) among prem…

Sponsor: NRG Oncology
NCT ID: NCT05879926
Sites in Missouri:
  • Mercy Oncology and Hematology - Clayton-Clarkson — Ballwin, Missouri
  • Central Care Cancer Center - Bolivar — Bolivar, Missouri
  • Cox Cancer Center Branson — Branson, Missouri
  • Mercy Cancer Center - Cape Girardeau — Cape Girardeau, Missouri
  • Saint Francis Medical Center — Cape Girardeau, Missouri
View on ClinicalTrials.gov →
Phase 3 Recruiting Network

Shorter Chemo-Immunotherapy Without Anthracycline Drugs for Early-Stage Triple Negative Breast Cancer

This phase III trial compares the effects of shorter chemotherapy (chemo)-immunotherapy without anthracyclines to usual chemo-immunotherapy for the treatment of early-stage triple negative breast cancer. Paclitaxel is in a class of medicat…

Sponsor: SWOG Cancer Research Network
NCT ID: NCT05929768
Sites in Missouri:
  • Mercy Oncology and Hematology - Clayton-Clarkson — Ballwin, Missouri
  • Central Care Cancer Center - Bolivar — Bolivar, Missouri
  • Cox Cancer Center Branson — Branson, Missouri
  • Mercy Cancer Center - Cape Girardeau — Cape Girardeau, Missouri
  • Saint Francis Medical Center — Cape Girardeau, Missouri
View on ClinicalTrials.gov →
Phase 3 Recruiting Academic/Other

Pembrolizumab vs. Observation in People With Triple-negative Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Pembrolizumab

This phase III trial compares the effect of continuation of treatment with pembrolizumab (usual approach) to observation only at preventing cancer from coming back in patients with early-stage triple-negative breast cancer (TNBC) who achie…

Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT05812807
Sites in Missouri:
  • Mercy Oncology and Hematology - Clayton-Clarkson — Ballwin, Missouri
  • Saint Francis Medical Center — Cape Girardeau, Missouri
  • Siteman Cancer Center at Saint Peters Hospital — City of Saint Peters, Missouri
  • MU Health - University Hospital/Ellis Fischel Cancer Center — Columbia, Missouri
  • Siteman Cancer Center at West County Hospital — Creve Coeur, Missouri
View on ClinicalTrials.gov →
Phase 3 Recruiting Academic/Other

De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA)

This Phase III Trial evaluates whether breast conservation surgery and endocrine therapy results in a non-inferior rate of invasive or non-invasive ipsilateral breast tumor recurrence (IBTR) compared to breast conservation with breast radi…

Sponsor: NRG Oncology
NCT ID: NCT04852887
Sites in Missouri:
  • Saint Francis Medical Center — Cape Girardeau, Missouri
  • Siteman Cancer Center at Saint Peters Hospital — City of Saint Peters, Missouri
  • MU Health - University Hospital/Ellis Fischel Cancer Center — Columbia, Missouri
  • Siteman Cancer Center at West County Hospital — Creve Coeur, Missouri
  • Parkland Health Center - Farmington — Farmington, Missouri
View on ClinicalTrials.gov →
Phase 3 Recruiting Network

S1501 Dual Observational and Randomized Cohort Study of Patients With Metastatic HER-2+ Breast Cancer at Risk of Cardiac Toxicity

This trial has two cohorts of patients with human epidermal growth factor receptor (HER)-2-positive breast cancer that has spread to other places in the body. All patients must be receiving trastuzumab-based treatment. Both cohorts are bei…

Sponsor: SWOG Cancer Research Network
NCT ID: NCT03418961
Sites in Missouri:
  • Saint Louis Cancer and Breast Institute-Ballwin — Ballwin, Missouri
  • Central Care Cancer Center - Bolivar — Bolivar, Missouri
  • Parkland Health Center-Bonne Terre — Bonne Terre, Missouri
  • Cox Cancer Center Branson — Branson, Missouri
  • Saint Francis Medical Center — Cape Girardeau, Missouri
View on ClinicalTrials.gov →
Phase 3 Recruiting Academic/Other

E-Mindfulness Approaches for Living After Breast Cancer

NRG-CC015 is a prospective, randomized phase III clinical trial to evaluate the efficacy of two distinct digital approaches for delivering a mindfulness-based intervention: a live, instructor-led version delivered over Zoom (MAPs LO), and …

Sponsor: NRG Oncology
NCT ID: NCT06748222
Sites in Missouri:
  • Lake Regional Hospital — Osage Beach, Missouri
  • Heartland Regional Medical Center — Saint Joseph, Missouri
  • Mercy Hospital Springfield — Springfield, Missouri
  • Mercy Hospital South — St Louis, Missouri
  • Missouri Baptist Medical Center — St Louis, Missouri
View on ClinicalTrials.gov →
Phase 3 Recruiting NIH

Testing Whether Hormone Therapy With Ribociclib is as Effective as Chemotherapy Followed by Hormone Therapy With Ribociclib for the Treatment of High Anatomic Stage Breast Cancer With Low Recurrence Risk, The RxFINE-Low Trial

This phase III trial compares standard of care hormone therapy plus ribociclib to chemotherapy followed by hormone therapy plus ribociclib for the treatment of patients with high anatomic stage breast cancer with low risk of the cancer ret…

Sponsor: National Cancer Institute (NCI)
NCT ID: NCT07391774
Sites in Missouri:
  • Mercy Oncology and Hematology - Clayton-Clarkson — Ballwin, Missouri
  • Saint Francis Medical Center — Cape Girardeau, Missouri
  • Parkland Health Center - Farmington — Farmington, Missouri
  • University of Kansas Cancer Center - Briarcliff — Kansas City, Missouri
  • University of Kansas Cancer Center - North — Kansas City, Missouri
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence

The primary goal of this study is to evaluate the effectiveness of elacestrant versus standard endocrine therapy in participants with node-positive, Estrogen Receptor-positive (ER+), Human Epidermal Growth Factor-2 negative (HER2-) early b…

Sponsor: Stemline Therapeutics, Inc.
NCT ID: NCT06492616
Sites in Missouri:
  • Siteman Cancer Center — St Louis, Missouri
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)

The purpose of the study is to assess the efficacy and safety of the addition of Tersolisib (LY4064809/STX-478) to other anti-cancer drugs as first treatment for advanced hormone receptor-positive (HR+)/human epidermal growth factor recept…

Sponsor: Eli Lilly and Company
NCT ID: NCT07174336
Sites in Missouri:
  • Saint Luke's Cancer Institute — Kansas City, Missouri
  • Oncology Hematology Associates — Springfield, Missouri
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.

The purpose of this study is to learn about the safety and effects of the study medicine PF-07248144 when given along with fulvestrant for the possible treatment of HR-positive, HER2-negative advanced or metastatic breast cancer. HR-positi…

Sponsor: Pfizer
NCT ID: NCT07062965
Sites in Missouri:
  • Siteman Cancer Center - St Peters — City of Saint Peters, Missouri
  • Siteman Cancer Center - North County — Florissant, Missouri
  • Saint Luke's Hospital of Kansas City — Kansas City, Missouri
  • Siteman Cancer Center — St Louis, Missouri
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)

Researchers are looking for new ways to treat types of breast cancer that are both: * High-risk, which means the cancer may have a higher chance of getting worse or coming back after treatment * Early-stage, which means the cancer is in th…

Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT06966700
Sites in Missouri:
  • Saint Luke's Cancer Institute ( Site 0059) — Kansas City, Missouri
  • Washington University Siteman Cancer Center ( Site 0031) — St Louis, Missouri
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer

This study will evaluate the efficacy and safety of the combination of inavolisib plus a cyclin-dependent kinase 4 and 6 inhibitor (CDK4/6i) and letrozole versus placebo plus a CDK4/6i and letrozole in the first-line setting in participant…

Sponsor: Hoffmann-La Roche
NCT ID: NCT06790693
Sites in Missouri:
  • HCA Midwest Health — Kansas City, Missouri
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer

This phase 3 clinical trial compares the efficacy and safety of palazestrant with ribociclib to letrozole and ribociclib in women and men who have not received prior systemic anti-cancer treatment for advanced breast cancer.

Sponsor: Olema Pharmaceuticals, Inc.
NCT ID: NCT07085767
Sites in Missouri:
  • Clinical Trial Site — Kansas City, Missouri
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer

This is a global, multicenter, open-label, randomized Phase 3 study comparing the efficacy and safety of RLY-2608 (zovegalisib) + fulvestrant to capivasertib + fulvestrant for the treatment of patients with HR+/HER2- ABC with PIK3CA mutati…

Sponsor: Relay Therapeutics, Inc.
NCT ID: NCT06982521
Sites in Missouri:
  • Washington University School of Medicine- Siteman Cancer Center — St Louis, Missouri
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation

The goal of this clinical trial is to assess the efficacy, safety and tolerability of the combination of lasofoxifene and abemaciclib compared to fulvestrant and abemaciclib for the treatment of pre- and postmenopausal women and men who ha…

Sponsor: LeonaBio
NCT ID: NCT05696626
Sites in Missouri:
  • Saint Luke's Cancer Institute — Kansas City, Missouri
  • Washington University School of Medicine — St Louis, Missouri
View on ClinicalTrials.gov →
Phase 2 Recruiting Industry

A Study of Alisertib in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Recurrent or Metastatic Breast Cancer

PUMA-ALI-1201 is a randomized, dose optimization, multicenter, Phase 2 study of alisertib administered in combination with endocrine therapy in participants with pathology-confirmed HR-positive/HER2-negative metastatic breast cancer (MBC) …

Sponsor: Puma Biotechnology, Inc.
NCT ID: NCT06369285
Sites in Missouri:
  • Missouri Cancer Associates — Columbia, Missouri
  • Saint Luke's Cancer Institute — Kansas City, Missouri
  • Oncology Hematology Associates — Springfield, Missouri
  • Washington University School of Medicine — St Louis, Missouri
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors

Study STX-478-101 (LY4064809) is a multipart, open-label, phase 1/2 study evaluating the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of STX-478 (LY4064809) in participants with advanced solid tumors with…

Sponsor: Eli Lilly and Company
NCT ID: NCT05768139
Sites in Missouri:
  • Saint Luke's Cancer Institute — Kansas City, Missouri
  • Washington University — St Louis, Missouri
View on ClinicalTrials.gov →
Phase 2 Recruiting Industry

ASPEN-09-03: A Study of Evorpacept in Combination With Trastuzumab and Chemotherapy in Metastatic HER2-Positive Breast Cancer

The Substudy Protocol ASPEN-09-03 is a Phase 2, single-arm, multicenter study evaluating the efficacy, safety, and tolerability of evorpacept in combination with trastuzumab and chemotherapy in participants with HER2-positive metastatic br…

Sponsor: ALX Oncology Inc.
NCT ID: NCT07007559
Sites in Missouri:
  • Washington University School of Medicine- Siteman Cancer Center — St Louis, Missouri
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid Tumors

The purpose of this study is to evaluate the safety, tolerability, drug levels, and preliminary efficacy of BMS-986507 combinations in adult participants with advanced solid tumors.

Sponsor: Bristol-Myers Squibb
NCT ID: NCT06618287
Sites in Missouri:
  • Local Institution - 0140 — St Louis, Missouri
View on ClinicalTrials.gov →
Phase 2 Recruiting Industry

A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors

This is a proof-of-concept study designed to investigate HER3-DXd monotherapy in locally advanced unresectable or metastatic solid tumors. The study is enrolling cohorts of participants with melanoma \[cutaneous/acral\], squamous cell carc…

Sponsor: Daiichi Sankyo
NCT ID: NCT06172478
Sites in Missouri:
  • Washington University, School of Medicine — St Louis, Missouri
View on ClinicalTrials.gov →
Phase 2 Recruiting NIH

Finding the Best Tamoxifen Dose for Breast Cancer Risk Reduction in Premenopausal Women, RENAISSANCE Trial

This phase II trial evaluates response-guided low-dose tamoxifen for reducing breast density in women who are at higher than average risk for breast cancer. Increasing breast density is a well established risk factor for breast cancer. Tam…

Sponsor: National Cancer Institute (NCI)
NCT ID: NCT06184750
Sites in Missouri:
  • Washington University School of Medicine — St Louis, Missouri
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

A Study of Sacituzumab Govitecan Given at an Alternative Dose and Schedule in Participants With Advanced Triple-Negative Breast Cancer

The goal of this clinical study is to learn more about the study drug sacituzumab govitecan-hziy (SG) given at an alternative dose and schedule, in participants with triple-negative breast cancer (TNBC). The primary objectives of this stud…

Sponsor: Gilead Sciences
NCT ID: NCT06926920
Sites in Missouri:
  • Siteman Cancer Center — St Louis, Missouri
View on ClinicalTrials.gov →
Phase 2 Recruiting Academic/Other

Trial of Neoadjuvant THP vs TCHP for HER2-Amplified/Positive Breast Cancer

This is a randomized phase II study to evaluate the pathological complete response (pCR) rate with two neoadjuvant regimens (Docetaxel+Carboplatin+Herceptin/Perjeta and Docetaxel+Herceptin/Perjeta) in HER2 amplified/positive early breast c…

Sponsor: University of Kansas Medical Center
NCT ID: NCT07220135
Sites in Missouri:
  • The University of Kansas Cancer Center - North — Kansas City, Missouri
  • KUCC - Lee's Summit — Lee's Summit, Missouri
View on ClinicalTrials.gov →
Phase 2 Recruiting Academic/Other

Functional Imaging in Prediction of Response to Abemaciclib for Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer

This phase II trial tests the accuracy of functional imaging (FFNP)-positron emission tomography (PET)/computed tomography (CT) to predict response to abemaciclib plus endocrine therapy. Abemaciclib is a drug used to treat certain types of…

Sponsor: University of Washington
NCT ID: NCT06179303
Sites in Missouri:
  • Siteman Cancer Center at Washington University — St Louis, Missouri
View on ClinicalTrials.gov →

Showing 25 of 48 trials with sites in Missouri. See all breast cancer trials →

Medical disclaimer: This page aggregates public ClinicalTrials.gov data. It is not medical advice. Always confirm eligibility and enrollment details with the trial site or your oncologist.

Source: ClinicalTrials.gov API v2 · Last checked: 2026-10-19